Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGvHD biomarkers Blood Adv
HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia Biomark Res
The Discovery, Characterization, and Quantification of Bioactive Peptides Contained in Palbio Porcine Intestinal Mucosa Hydrolysate Products Int J Mol Sci
Corrigendum to "Opposing effects of the purinergic P2X7 receptor on seizures in neurons and microglia in male mice" [Brain Behav. Immun. 120 (2024) 121-140] Brain Behav Immun
Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease J Hepatol
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia Blood Neoplasia
Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols MED CLIN-BARCELONA
Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma Future Oncol
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial Lancet Oncol